Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
PURPOSE: The current study compared the standard response assessment in neuro-oncology (RANO), immunotherapy RANO (iRANO), and modified RANO (mRANO) criteria as well as quantified the association between progression-free (PFS) and overall survival (OS) in an immunotherapy trial in recurrent glioblastoma (rGBM).
PATIENTS AND METHODS: A total of 47 patients with rGBM were enrolled in a prospective phase II convection-enhanced delivery of an IL4R-targeted immunotoxin (MDNA55-05, NCT02858895). Bidirectional tumor measurements were created by local sites and centrally by an independent radiologic faculty, then standard RANO, iRANO, and mRANO criteria were applied.
RESULTS: A total of 41 of 47 patients (mean age 56 ± 11.7) were evaluable for response. PFS was significantly shorter using standard RANO compared with iRANO (log-rank,
CONCLUSIONS: No correlation between radiographic PFS and OS was observed for standard RANO or iRANO, but a correlation was observed between PFS and OS using the mRANO criteria. Also, the iRANO criteria was difficult to implement due to need to confirm progression 3 months after initial progression, censoring more than half the patients.
Neurosciences (Brain & Spine)
Ellingson, Benjamin M; Sampson, John; Achrol, Achal Singh; Aghi, Manish K; Bankiewicz, Krystof; Wang, Chencai; Bexon, Martin; Brem, Steven; Brenner, Andrew; Chowdhary, Sajeel; Floyd, John R; Han, Seunggu; Kesari, Santosh; Randazzo, Dina; Vogelbaum, Michael A; Vrionis, Frank; Zabek, Miroslaw; Butowski, Nicholas; Coello, Melissa; Merchant, Nina; and Merchant, Fahar, "Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma." (2021). Articles, Abstracts, and Reports. 4771.